Literature DB >> 17458595

Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis.

R R White1, I Avital, C T Sofocleous, K T Brown, L A Brody, A Covey, G I Getrajdman, W R Jarnagin, R P Dematteo, Y Fong, L H Blumgart, M D'Angelica.   

Abstract

INTRODUCTION: The purpose of this study was to compare rates and patterns of disease progression following percutaneous, image-guided radiofrequency ablation (RFA) and nonanatomic wedge resection for solitary colorectal liver metastases.
METHODS: We identified 30 patients who underwent nonanatomic wedge resection for solitary liver metastases and 22 patients who underwent percutaneous RFA because of prior major hepatectomy (50%), major medical comorbidities (41%), or relative unresectability (9%). Serial imaging studies were retrospectively reviewed for evidence of local tumor progression.
RESULTS: Patients in the RFA group were more likely to have undergone prior liver resection, to have a disease-free interval greater than 1 year, and to have had an abnormal carcinoembryonic antigen (CEA) level before treatment. Two-year local tumor progression-free survival (PFS) was 88% in the Wedge group and 41% in the RFA group. Two patients in the RFA group underwent re-ablation, and two patients underwent resection to improve the 2-year local tumor disease-free survival to 55%. Approximately 30% of patients in each group presented with distant metastasis as a component of their first recurrence. Median overall survival from the time of resection was 80 months in the Wedge group vs 31 months in the RFA group. However, overall survival from the time of treatment of the colorectal primary was not significantly different between the two groups.
CONCLUSIONS: Local tumor progression is common after percutaneous RFA. Surgical resection remains the gold standard treatment for patients who are candidates for resection. For patients who are poor candidates for resection, RFA may help to manage local disease, but close follow-up and retreatment are necessary to achieve optimal results.

Entities:  

Mesh:

Year:  2007        PMID: 17458595     DOI: 10.1007/s11605-007-0100-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  29 in total

1.  Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year.

Authors:  T de Baere; D Elias; C Dromain; M G Din; V Kuoch; M Ducreux; V Boige; N Lassau; V Marteau; P Lasser; A Roche
Journal:  AJR Am J Roentgenol       Date:  2000-12       Impact factor: 3.959

2.  Laparoscopic radiofrequency ablation of unresectable hepatic malignancies. A phase 2 trial.

Authors:  M H Chung; T F Wood; G J Tsioulias; D M Rose; A J Bilchik
Journal:  Surg Endosc       Date:  2001-06-12       Impact factor: 4.584

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

5.  Hepatic resection for metastatic colorectal cancer results in cure for some patients.

Authors:  R L Jamison; J H Donohue; D M Nagorney; C B Rosen; W S Harmsen; D M Ilstrup
Journal:  Arch Surg       Date:  1997-05

6.  Interval hepatic resection of colorectal metastases improves patient selection.

Authors:  L A Lambert; T A Colacchio; R J Barth
Journal:  Arch Surg       Date:  2000-04

7.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

8.  Large-volume tissue ablation with radio frequency by using a clustered, internally cooled electrode technique: laboratory and clinical experience in liver metastases.

Authors:  S N Goldberg; L Solbiati; P F Hahn; E Cosman; J E Conrad; R Fogle; G S Gazelle
Journal:  Radiology       Date:  1998-11       Impact factor: 11.105

9.  Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases.

Authors:  Peter J Allen; Nancy Kemeny; William Jarnagin; Ronald DeMatteo; Leslie Blumgart; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

10.  Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned.

Authors:  Richard J Bleicher; David P Allegra; Dean T Nora; Thomas F Wood; Leland J Foshag; Anton J Bilchik
Journal:  Ann Surg Oncol       Date:  2003 Jan-Feb       Impact factor: 5.344

View more
  46 in total

1.  CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

2.  Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs.

Authors:  Maria A Cassera; Kevin W Potter; Michael B Ujiki; Lee L Swanström; Paul D Hansen
Journal:  Surg Endosc       Date:  2010-09-17       Impact factor: 4.584

Review 3.  Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies.

Authors:  Gianpiero Gravante; John Overton; Roberto Sorge; Neil Bhardwaj; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2011-02       Impact factor: 3.452

Review 4.  [Interventional procedures for hepatic metastases].

Authors:  T Helmberger
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

Review 5.  Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer.

Authors:  Aaron T Wild; Yoshiya Yamada
Journal:  Visc Med       Date:  2017-02-03

6.  Hepatectomy vs radiofrequency ablation for colorectal liver metastasis: a propensity score analysis.

Authors:  Huisong Lee; Jin Seok Heo; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Woo Yong Lee; Seong Ho Choi; Dong Wook Choi
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

7.  Fluorescent Tissue Assessment of Colorectal Cancer Liver Metastases Ablation Zone: A Potential Real-Time Biomarker of Complete Tumor Ablation.

Authors:  Vlasios S Sotirchos; Sho Fujisawa; Efsevia Vakiani; Stephen B Solomon; Katia O Manova-Todorova; Constantinos T Sofocleous
Journal:  Ann Surg Oncol       Date:  2019-03-04       Impact factor: 5.344

8.  Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases.

Authors:  Sanghwa Ko; Hongjae Jo; Seongpil Yun; Eunyoung Park; Suk Kim; Hyung-Il Seo
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

9.  Radiofrequency ablation vs. hepatic resection for resectable colorectal liver metastases.

Authors:  Nan He; Qian-Na Jin; Di Wang; Yi-Ming Yang; Yu-Lin Liu; Guo-Bin Wang; Kai-Xiong Tao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

Review 10.  Optimal management of colorectal liver metastases in older patients: a decision analysis.

Authors:  Simon Yang; Shabbir M H Alibhai; Erin D Kennedy; Abraham El-Sedfy; Matthew Dixon; Natalie Coburn; Alex Kiss; Calvin H L Law
Journal:  HPB (Oxford)       Date:  2014-06-24       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.